Publicado

2022-08-03

Treatment approach to a patient with catamenial epilepsy. Case report

Abordaje de una paciente con epilepsia catamenial. Reporte de caso

DOI:

https://doi.org/10.15446/cr.v8n1.91649

Palabras clave:

Epilepsy, Menstrual cycle, Neurosteroids, Progesterone, Estrogen, Drug Resistant Epilepsy (en)
Ciclo Menstrual, Epilepsia refractaria, Neuroesteroides, Progesterona, Estrógeno (es)

Autores/as

Introduction: Catamenial epilepsy refers to the worsening or exacerbation of seizures due to hormonal changes during the menstrual cycle. It is thought to be secondary to the neuroactive properties of endogenous steroid hormones and the natural cyclic variation in their serum levels throughout the menstrual cycle.

Case presentation: A 31-year-old female patient from Bogotá (Colombia) was admitted to the emergency department due to an episode of tonic-clonic seizure associated with the menstrual period. Since the onset of the seizures was related to menstruation (every 28 days), it was established that the patient had structural focal epilepsy with catamenial features. Advantages of medical vs. surgical treatment were discussed during a multidisciplinary medical board and it was decided to start pharmacological treatment with progestogens, which resulted in complete remission of the seizures as established during a follow-up visit.

Conclusions: Catamenial epilepsy should be considered as a cause of epilepsy refractory to antiepileptic medications. Furthermore, it should be approached from a multidisciplinary perspective and its management should be focused on improving the patients’ quality of life.

Introducción. La epilepsia catamenial se define como un empeoramiento o la exacerbación de las crisis epilépticas en relación con el cambio hormonal durante el ciclo menstrual femenino. Se cree que esta se produce por las propiedades neuroactivas de las hormonas esteroides endógenas y la variación cíclica natural en sus niveles séricos a lo largo de dicho ciclo.

Presentación del caso. Mujer de 31 años de Bogotá (Colombia), quien fue llevada al servicio de urgencias por un episodio de crisis epiléptica con convulsiones tonicoclónicas asociado al período menstrual. Debido a que la aparición de las crisis epilépticas se asociaba con la menstruación (cada 28 días), se estableció que la paciente presentaba epilepsia focal estructural de características catameniales. En junta médica multidisciplinar se discutieron las ventajas del manejo médico y el manejo quirúrgico, y se decidió instaurar tratamiento farmacológico con progestágenos, el cual, tras seguimiento, evidenció supresión total de las crisis.

Conclusiones. La epilepsia catamenial debe considerarse como una causa de epilepsia refractaria al tratamiento antiepiléptico. Además, su abordaje debe ser multidisciplinario y su tratamiento debe ir enfocado a mejorar la calidad de vida de los pacientes.

Referencias

Patel SI, Foldvary-Schaefer N. Catamenial epilepsy. In: Bui E, Klein A, editors. Women with Epilepsy. Cambridge: Cambridge University Press; 2014. p. 101-12. https://doi.org/hkqk.

Singh A, Trevick S. The Epidemiology of Global Epilepsy. Neurol Clin. 2016;34(4):837-47. https://doi.org/f88632.

Velez A, Eslava-Cobos J. Epilepsy in Colombia: Epidemiologic Profile and Classification of Epileptic Seizures and Syndromes. Epilepsia. 2006;47(1):193-201. https://doi.org/cfvfjs.

Herzog AG, Klein P, Rand BJ. Three Patterns of Catamenial Epilepsy. Epilepsia. 1997;38(10):1082-8. https://doi.org/dd9pzd.

Duncan S, Read CL, Brodie MJ. How Common Is Catamenial Epilepsy? Epilepsia. 1993;34(5):827-31. https://doi.org/cvnd94.

Maguire MJ, Nevitt SJ. Treatments for seizures in catamenial (Menstrual-related) epilepsy. Cochrane Database Syst Rev. 2019;10(10):CD013225. https://doi.org/gg7f3d.

Verrotti A, D’Egidio C, Agostinelli S, Verrotti C, Pavone P. Diagnosis and management of catamenial seizures: a review. Int J Womens Health. 2012;4:535-41. https://doi.org/hkxr.

Castro-Martínez E. Epilepsia en la mujer. Ciudad de México: Editorial Grafisa, S.A. de C.V.; 2018.

Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav. 2013;63(2):254-66. https://doi.org/f4pgr9.

Haseitel M, Silva E. Trastornos hormonales en pacientes con epilepsia Hormonal Disorders in Patients with Epilepsy. Rev Argent Endocrinol Metab. 2015;52(2):108-12.

Joshi S, Kapur J. Neurosteroid regulation of GABA-A receptors: A role in catamenial epilepsy. Brain Res. 2019;1703:31-40. https://doi.org/hkxs.

Reddy DS, Kim H-Y, Rogawski MA. Neurosteroid Withdrawal Model of Perimenstrual Catamenial Epilepsy. Epilepsia. 2002;42(3):328-36. https://doi.org/ckjx64.

Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia. 2001;42(3):337-44. https://doi.org/cws4qw.

Taubøll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure. 2015;28:3-11. https://doi.org/f7dpr5.

Voinescu PE. Catamenial Epilepsy. In: O’Neal M, editor. Neurology and Psychiatry of Women. Cham: Springer International Publishing; 2019. p. 85-94. https://doi.org/hkwv.

Herzog AG. Catamenial epilepsy: definition, prevalence pathophysiology and treatment. Seizure. 2008;17(2):151-9. https://doi.org/cwtd7g.

Guille C, Spencer S, Cavus I, Epperson CN. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: Implications for diagnosis and treatment. Epilepsy Behav. 2008;13(1):12-24. https://doi.org/bwdd6n.

Contreras A, Fabres L. Epilepsia y mujer. Rev Médica Clínica Las Condes. 2013;24(6):928-37. https://doi.org/f2x5dd.

Kandeepan J, Shaaban J. Catamenial epilepsy: A missed cause of refractory seizure in young women. Malays Fam Physician. 2016;11(2-3):24-6.

Najafi M, Sadeghi M, Mehvari J, Zare M, Akbari M. Progesterone therapy in women with intractable catamenial epilepsy. Adv Biomed Res. 2013;2(1):8. https://doi.org/gb9w6c.

Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology. 1984;34(9):1255-8. https://doi.org/hkxk.

Bauer J, Wild L, Flügel D, Stefan H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J Neurol. 1992;239(5):284-6.

Herzog AG. Clomiphene therapy in epileptic women with menstrual disorders. Neurology. 1988;38(3):432-4. https://doi.org/hkxt.

Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009;6(2):392-401. https://doi.org/cvwjpv.

Navis A, Harden C. A Treatment Approach to Catamenial Epilepsy. Curr Treat Options Neurol. 2016;18(7):30. https://doi.org/f8tpgz.

Vilos GA, Hollett-Caines J, Abu-Rafea B, Ahmad R, Mazurek MF. Resolution of Catamenial Epilepsy after Goserelin Therapy and Oophorectomy: Case Report of Presumed Cerebral Endometriosis. J Minim Invasive Gynecol. 2011;18(1):128-30. https://doi.org/fpj54h.

Dimensions

PlumX

Visitas a la página del resumen del artículo

629

Descargas

Los datos de descarga aún no están disponibles.

Cómo citar

Abordaje de una paciente con epilepsia catamenial. Reporte de caso. (2022). Case Reports, 8(1), 105-115. https://doi.org/10.15446/cr.v8n1.91649